Related Experiment Video
Updated: Apr 27, 2026
Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
Novel inhibitors of macrophage migration inhibitory factor prevent cytokine-induced beta cell death
Milica Vujicic1, Ivana Nikolic1, Tamara Krajnovic1
1Department of Immunology, Institute for Biological Research "Sinisa Stankovic", University of Belgrade, Belgrade, Serbia.
Abstract:
Macrophage migration inhibitory factor is a multifunctional cytokine involved in the regulation of immune processes and also in apoptosis induction. Elevated MIF expression is detrimental for insulin-producing beta cells and MIF inhibition protected beta cells from several cytotoxic insults such as inflammatory cytokines, high fatty acids or high glucose concentrations. Therefore, the aim of this study was to investigate two newly synthesized small molecule MIF inhibitors (K664-1 and K647-1) and to compare them with previously established effects of the prototypical MIF inhibitor, ISO-1. Our results indicate that K664-1 and K647-1 are 160- and 40-fold more effective in inhibition of MIF׳s tautomerase activity than ISO-1. Also, new inhibitors confer beta cell protection from cytokine-triggered apoptosis at significantly lower concentrations than ISO-1. Although all three MIF inhibitors inhibit caspase 3 activity, K664-1 and K647-1 suppress pro-apoptotic BAX protein expression and up-regulate anti-apoptotic Bcl-2 mRNA. Finally, all three MIF inhibitors operate through blockade of nitric oxide production stimulated by cytokines. In conclusion, two novel MIF inhibitors are more potent than ISO-1 and operate through inhibition of the mitochondria-related apoptotic pathway. We propose that these compounds represent a unique class of anti-MIF antagonists that should be further tested for therapeutic use.
Insights
Two new small molecule inhibitors, K664-1 and K647-1, are potent inhibitors of macrophage migration inhibitory factor (MIF). These compounds offer superior beta cell protection against apoptosis compared to existing MIF inhibitors.
Area of Science:
- Immunology
- Cell Biology
- Endocrinology
Background:
- Macrophage migration inhibitory factor (MIF) is a cytokine implicated in immune regulation and apoptosis.
- Elevated MIF levels harm insulin-producing beta cells, making MIF inhibition a potential therapeutic strategy.
- Previous MIF inhibitors like ISO-1 have shown protective effects on beta cells.
Purpose of the Study:
- To evaluate the efficacy of two novel small molecule MIF inhibitors, K664-1 and K647-1.
- To compare the potency and protective effects of K664-1 and K647-1 against the established MIF inhibitor ISO-1.
- To elucidate the mechanism of action of these novel MIF inhibitors in beta cell protection.
Main Methods:
- Assessed the tautomerase inhibitory activity of K664-1, K647-1, and ISO-1.
- Determined the protective effects of MIF inhibitors against cytokine-induced beta cell apoptosis.
- Analyzed caspase 3 activity, BAX protein expression, and Bcl-2 mRNA levels.
- Investigated the role of nitric oxide production in MIF inhibitor-mediated protection.
Main Results:
- K664-1 and K647-1 demonstrated significantly higher potency in inhibiting MIF tautomerase activity compared to ISO-1 (160- and 40-fold, respectively).
- The novel inhibitors provided beta cell protection from cytokine-induced apoptosis at lower concentrations than ISO-1.
- K664-1 and K647-1 modulated apoptotic pathways by suppressing BAX and up-regulating Bcl-2.
- All tested MIF inhibitors blocked cytokine-stimulated nitric oxide production.
Conclusions:
- K664-1 and K647-1 are more potent MIF inhibitors than ISO-1.
- These novel compounds protect beta cells by inhibiting the mitochondria-related apoptotic pathway.
- K664-1 and K647-1 represent a promising new class of anti-MIF agents for potential therapeutic development.
